Biocon Biologics Eyes USD 75 Billion Oncology Market, Adds 3 New Biosimilar Drugs

Day 1 conference highlights include news from Moderna, BridgeBio

DRRA10 hours ago 0

FDA again rejects tabelecleucel for EBV-driven post-transplant lymphoproliferative disease

DRRA10 hours ago 0

New data, nuances in managing resistant gram-negative infections

DRRA11 hours ago 0

New Year’s resolutions 2026: Lessons from colleagues

DRRA12 hours ago 0